logo

Delmar Pharmaceuticals, Inc. (DMPI)



Trade DMPI now with
  Date
  Headline
8/14/2019 9:12:33 AM DelMar Pharma Announces Pricing Of $6.8 Mln Underwritten Public Offering
8/13/2019 9:03:44 AM DelMar Reports Updated Results On Twenty Patients From The Phase 2 Clinical Trial Of VAL-083
7/24/2019 9:00:51 AM DelMar Enrolls First Patient In Adjuvant Setting Arm Of Phase 2 Study Of VAL-083 For Treatment Of MGMT
6/27/2019 5:32:44 AM Delmar Pharmaceuticals Announces Termination Of Rights Offering
6/11/2019 5:33:31 AM Delmar Adjusts Certain Pricing Information And Key Dates For Previously Announced Rights Offering
6/3/2019 8:52:18 AM DelMar Updates On VAL-083 From Ongoing First- And Second-Line Trials In Patients With MGMT-unmethylated Glioblastoma
6/3/2019 8:50:57 AM DelMar Plans $3.6 Mln Registered Direct Offering
5/20/2019 5:32:47 AM DelMar Appoints Three Additional World-class Neuro-oncologists To Its Scientific Advisory Board
5/15/2019 5:36:23 AM DelMar Pharma Q3 Net Loss Narrows To $1.66 Mln From $2.93 Mln Last Year
5/7/2019 4:55:40 PM DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split
4/3/2019 5:34:14 AM DelMar Receives Approval From MD Anderson Cancer Center's IRB For Protocol Expansion
2/20/2019 5:32:19 AM DelMar Reports Halfway Enrollment Point For Phase 2 Clinical Trial Of VAL-083 In Newly Diagnosed MGMT-unmethylated GBM
2/7/2019 5:32:42 AM DelMar Pharma Receives Nasdaq Listing Extension Until June 25, 2019
11/20/2018 5:33:21 AM DelMar Presents Clinical Update On VAL-083 From Ongoing First- And Second-Line Trials At SNO Annual Meeting
11/14/2018 5:34:05 AM DelMar Pharma Q1 Net Loss $1.99 Mln Or $0.09/Shr Vs Loss Of $2.67 Mln Or $0.18/Shr Last Year